Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells
The U.S. issued patent broadly covers methods and apparatus used for the capture of target biomolecules, including cells of interest, using microchannels that disrupt flow to aid capture. The Canadian patent covers the capture of target cells, including CTCs, using a combination of binding partners and methods for capture on any surface. The European patent encompasses methods for enhancing the detection of cells using fluorescent complexes. The combination of these patents significantly expands the breadth of intellectual property protection for
"Collectively, the granting of these additional patents further broadens
"Increasing shareholder value by broadening U.S. and international patent protection used in our Target Selector™ liquid biopsy platform is a key strategic initiative, as we seek to develop our business globally, with the potential to license our technologies for uses outside the scope of our core business," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including, without limitation, statements as to our ability to improve the management, diagnosis and treatment of cancer, the ability of our tests to provide clinically actionable information to oncologist and their patients, our ability to expand our business globally and expand the adoption of our tests, and opportunities to license our technologies for a variety of uses, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-receives-three-additional-patents-covering-its-antibody-and-microchannel-technology-and-enhanced-detection-of-cancer-cells-300900469.html
SOURCE